Dongkook Pharmaceutical stock posts record Q2 revenue

Published on 09/30/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dongkook Pharmaceutical stock posted KRW 258.9 billion in Q2 2026 revenue, up 10.9 percent year over year. Uresco held 76.3 percent of its market in June.

Dongkook, KR7086450004, Illustration mit AI erstellt.

Dongkook Pharmaceutical stock (ISIN KR7086450004) is supported by Q2 2026 revenue of KRW 258.9 billion, a quarterly record and a 10.9 percent increase from a year earlier. The result gives the South Korean drugmaker a clear growth anchor, although profit conversion weakened compared with the previous quarter.

Revenue reaches a quarterly record

ATS View reported that DongKook Pharmaceutical's Q2 2026 revenue reached KRW 258.9 billion, compared with KRW 251.0 billion in Q1 2026. Operating profit was KRW 26.1 billion, producing a 10.1 percent margin, versus KRW 27.3 billion and a 10.9 percent margin in Q1.

The comparison highlights the main investor tension. Sales continued to expand, but operating profit declined by KRW 1.2 billion quarter over quarter, while net income fell from KRW 26.3 billion in Q1 to KRW 17.2 billion in Q2, according to the same Q2 results table.

Uresco expands its commercial reach

Uresco provides a second operating signal. As Edaily reported on September 28, 2026, the benign prostatic hyperplasia treatment held a 76.3 percent share of South Korea's dutasteride tadalafil combination market based on June data from UBIST.

The same report said Dongkook Pharmaceutical signed a licensing and supply agreement with Spain's Faes Farma covering 13 Latin American markets. That combination of domestic share and overseas distribution gives the product a measurable route for expansion beyond South Korea.

Stock remains below its yearly high

KOSDAQ shares were last at KRW 21,500 on September 30, 2026, at 3:30 p.m. KST. The 52-week range was KRW 16,260 to KRW 31,250, placing the latest price KRW 9,750 below the yearly high, while market capitalization stood at KRW 969.9 billion.